Menu
GWAS Study

A genome-wide association study of heparin-induced thrombocytopenia using an electronic medical record.

Karnes JH, Cronin RM, Rollin J et al.

25503805 PubMed ID
GWAS Study Type
1376 Participants
Scroll to explore
Chapter I

Publication Details

Comprehensive information about this research publication

Authors

KJ
Karnes JH
CR
Cronin RM
RJ
Rollin J
TA
Teumer A
PC
Pouplard C
SC
Shaffer CM
BC
Blanquicett C
BE
Bowton EA
CJ
Cowan JD
MJ
Mosley JD
VD
Van Driest SL
WP
Weeke PE
WQ
Wells QS
BT
Bakchoul T
DJ
Denny JC
GA
Greinacher A
GY
Gruel Y
RD
Roden DM
Chapter II

Abstract

Summary of the research findings

Heparin-induced thrombocytopenia (HIT) is an unpredictable, potentially catastrophic adverse effect of heparin treatment resulting from an immune response to platelet factor 4 (PF4)/heparin complexes. No genome-wide evaluations have been performed to identify potential genetic influences on HIT. Here, we performed a genome-wide association study (GWAS) and candidate gene study using HIT cases and controls identified using electronic medical records (EMRs) coupled to a DNA biobank and attempted to replicate GWAS associations in an independent cohort. We subsequently investigated influences of GWAS-associated single nucleotide polymorphisms (SNPs) on PF4/heparin antibodies in non-heparin treated individuals. In a recessive model, we observed significant SNP associations (odds ratio [OR] 18.52; 95% confidence interval [CI] 6.33-54.23; p=3.18×10(-9)) with HIT near the T-Cell Death-Associated Gene 8 (TDAG8). These SNPs are in linkage disequilibrium with a missense TDAG8 SNP. TDAG8 SNPs trended toward an association with HIT in replication analysis (OR 5.71; 0.47-69.22; p=0.17), and the missense SNP was associated with PF4/heparin antibody levels and positive PF4/heparin antibodies in non-heparin treated patients (OR 3.09; 1.14-8.13; p=0.02). In the candidate gene study, SNPs at HLA-DRA were nominally associated with HIT (OR 0.25; 0.15-0.44; p=2.06×10(-6)). Further study of TDAG8 and HLA-DRA SNPs is warranted to assess their influence on the risk of developing HIT.

57 European ancestry cases, 8 African American cases, 1 other ancestry cases, 1 case, 754 European ancestry controls, 108 African American controls, 6 other ancestry controls, 6 controls, 8 Hispanic controls, 1 Asian control

Chapter III

Study Statistics

Key metrics and study information

1376
Total Participants
GWAS
Study Type
Yes
Replicated
94 European ancestry cases, 178 European ancestry antibody positive controls, 154 European ancestry antibody negative controls
Replication Participants
Other, Asian unspecified, African American or Afro-Caribbean, European, Hispanic or Latin American
Ancestry
U.S.
Recruitment Country
Chapter IV

Analysis

Comprehensive review of health and genetic findings

Important Disclaimer: This review has been performed semi-automatically and is provided for informational purposes only. While we strive for accuracy, this analysis may contain errors, omissions, or misinterpretations of the original research. DNA Genics disclaims all liability for any inaccuracies, errors, or consequences arising from the use of this information. Users should independently verify all information and consult original research publications before making any decisions based on this content. This analysis is not intended as a substitute for professional scientific review or medical advice.

Analysis In Progress

Our analysis of this publication is currently being prepared. Please check back soon for comprehensive insights into the health and genetic findings discussed in this research.